secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001437749-24-024297
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M
------------------------------------------------------------------------------

- Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.
- GAAP net loss $4.5M ($0.09 loss per share) vs net income $2.1M ($0.05 EPS) in Q2 2023.
- Non-GAAP adjusted net loss $2.5M ($0.05 loss per share) vs adjusted net income $4.6M ($0.10 EPS).
- Cash & equivalents $96.8M at June 30, 2024; net cash from ops $1.0M in Q2.
- FY2024 guidance: net product revenue $183-190M, net income $12-15M; Q3 net product revenue $50-53M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924024297/0001437749-24-024297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924024297/pbyi20240731_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-024297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer